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Abstract
Background: Adenocarcinomas of the oral cavity are rare neoplasms, and only four cases of primary colonic
adenocarcinoma of the tongue have ever been described in literature. Very few information about chemotherapy
sensitiveness of this type of neoplasia is available, with only one regimen that showed some activity in a metastatic
patient.
Case presentation: We describe the case of a patient bearing a metastatic colonic adenocarcinoma of the
tongue submitted to a first-line chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid (FOLFOX regimen).
After chemotherapy the patient obtained the complete disappearance of the primitive neoplasia located in the
body of the tongue, and a tumor size reduction > 50% of liver and lung metastases.
Conclusions: This case demonstrated the activity of the combination of oxaliplatin and 5-fluorouracil in this very
rare neoplasia. The FOLFOX regimen might be considered either in advanced and especially in the neoadjuvant
setting, when the reduction of the primary tumor is highly needed.
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Background
In Western countries tumors of the oral cavity are rare and
account for four new cases every 1,000,000 persons/year in
Italy [1]. These tumors usually develop from precancerous
lesions such as leukoplakia, erythroplakia, sub mucosal fi-
brosis and lichen, or from continuous mucosal inflamma-
tion due to irregular tooth placement or damaged dental
prosthesis. However, in many cases the specific pathogen-
esis remains unknown. Tongue is the most common site
among Caucasians (40–50% of oral cancers). They are typ-
ically squamous cell carcinomas (95%), whereas adenocar-
cinomas, usually originating from minor salivary glands,
are rare and mainly reported in women and younger pa-
tients [2]. Similarly, primary colonic adenocarcinomas of
the tongue (CAT) are extremely uncommon, and only four
cases have been so far described [3–5], all of them with lo-
calized disease at diagnosis.
The case of a patient with an intestinal adenocarcin-
oma of the body of the tongue with synchronous distant
metastases responsive to FOLFOX regimen is here
reported.
Case presentation
In June 2013, a 75-year-old woman was diagnosed with a
solid mass located in the body of the tongue (Fig. 1) with
suspected lateral cervical and submandibular lymphnodes.
A biopsy of the tongue revealed an adenocarcinoma form-
ing invasive glandular structures with areas of luminal ne-
crosis. Immunohistochemical stainings yielded positivity
for CK20 and CDX2, and negativity for CK7, findings
compatible with a colonic adenocarcinoma subtype. Com-
puterized tomography (CT) with iodine contrast revealed
multiple lung metastases and a large hepatic lesion of
83 × 60 mm. The patient was subsequently submitted to
gastroscopy and colonoscopy, both negative for neoplastic
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disease. From September 2013 to March 2014 the patient
received 12 cycles of FOLFOX regimen. Treatment was
generally well tolerated with improvement of patient qual-
ity of life, reduction of dysphagia and recovery of a normal
eating. Body weight increased and local pain control was
satisfactory. The CT scan performed in April 2014, at the
end of the chemotherapy program (Fig. 2), showed the
complete response of the primary lesion, together with the
partial response of the lymphadenopathies and lung me-
tastases. Liver metastases presented conflicting findings
because the large secondary lesion decreased in size
(40 mm), but new satellite lesions were detected. Add-
itionally, a vertebral metastasis was clearly visible in the
body of L4 and a compound fracture was evident in the
left ischio-pubic branch. The patient was hospitalized in
May 2014 for uncontrolled pain. General condition pro-
gressively worsened preventing any further treatment and
finally she died in October 2014, 16 months after
diagnosis.
Discussion and conclusions
This is the first reported case of a primary colonic
adenocarcinoma of the tongue with synchronous metas-
tases, the first appeared in a woman and the fifth ever
described.
The histogenesis of this cancer is uncertain, but the
neoplastic transformation of a minor salivary duct epi-
thelium is quite likely. The hypothesis is supported by
the immunohistochemical profile of the tumor and by
studies of primary intestinal-type adenocarcinoma of the
sino-nasal tract where evidence of respiratory epithelium
transformation to an intestinal phenotype have been
noted in the adjacent non-neoplastic epithelium [6]. In
addition, the possibility that these tumors derived from a
gastrointestinal tract heterotopia within the tongue has
been proposed [7]. The tumor we reported was histolog-
ically similar to those of previous reports, with invasive
malignant glandular structures and no involvement of
the overlying squamous mucosa.
The mainstay of treatment of adenocarcinoma of the
oral cavity is surgery. Thus, neoadjuvant treatments may
result in better outcomes. However, the lack of know-
ledge due to the rarity of these neoplasms hampered the
definition of specific guidelines.
Differently from what we observed in our patient, all
the reported cases presented at diagnosis with
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Fig. 1 RMN scan of the oral cavity with a bulky, solid, infiltrating lesion of 47x27x22 mm of the body of the tongue, with central loss of
substance and irregular hyper-vascularity. Transversal (a), coronal (b), and sagittal (c) view
Fig. 2 CT scan after 6 months of chemotherapy showing the
complete disappearance of the tumor mass primarily located in
the body of the tongue
Zichi et al. BMC Cancer  (2018) 18:470 Page 2 of 3
locoregional lymphnodal metastases and no distant
metastases. Two patients [3] received unspecified and
inefficacious neo-adjuvant chemotherapy and were alive
without relapse of the disease 11 and 13 months after
surgery. One case [4] underwent surgery followed by ad-
juvant radiotherapy without chemotherapy. This latter
case was published when radiotherapy was ongoing and
thus no valid follow-up information was provided. The
last case [5] received carboplatin and taxol with radio-
therapy as post-resection adjuvant therapy. Patient re-
lapsed into the lung 14 months after diagnosis and then
received permetrexed and bevacizumab therapy with an
overall survival of 60 months.
Chemotherapy of adenocarcinoma of the oral cavity is
very heterogeneous and includes cisplatin, carboplatin,
paclitaxel, 5FU, anthracyclines, gemcitabine, and cyclo-
phosphamide, within others [8]. Little information about
systemic therapy of CAT is available. Due to the uncer-
tain outcome of the previous clinical reports we decided
to administer 5FU and oxaliplatin (FOLFOX schema).
This therapeutic decision was made because the more
extensively studied drugs in adenocarcinomas of the oral
cavity are platinum derivatives (cisplatin and carbopla-
tin) [8] and the combination of platinum with 5FU nor-
mally results in a synergistic activity [9]. In addition the
combination of oxaliplatin and 5FU is active against
either squamous cell carcinomas of the oral cavity and
adenocarcinomas of other origins including colorectal.
Chemotherapy was well tolerated with an immediate
clinical benefit; particularly dysphagia that early improved
allowing the patient a regular eating. Chemotherapy in-
duced a good local control of the disease, with significant
tumor shrinkage at the end of therapy, and a decrease in
size of liver and lung metastases. These results encourage
clinicians to consider FOLFOX regimen as neoadjuvant
treatment of CAT. It should be underlined that oxaliplatin
and 5FU might also be associated to radiotherapy, expand-
ing the possibility of treatment in locally advanced tumors.
Overall survival of patients bearing salivary gland car-
cinomas is heterogeneous, with 5-year survival of nearly
50% in high-grade tumors. Palliative chemotherapy did
not demonstrated to be highly active, with response rate
ranging from 20 to 25% down to 10% according to histo-
logical subtype, type of chemotherapy and reported
series [10]. The case we reported survived 16 months.
Unfortunately patient quality of life was hampered by
bone metastases and this clinical condition prevented
any further line of chemotherapy administration. To the
best of our knowledge, we report the first case of a re-
sponse to chemotherapy of the primary tumor. FOLFOX
regimen was well tolerated and showed high activity and
then should be considered when planning an induction
chemotherapy or chemo-radiotherapy prior to surgery in
locally advanced disease.
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